Intrust Bank NA Has $1.47 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Intrust Bank NA increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.3% in the fourth quarter, HoldingsChannel reports. The firm owned 1,673 shares of the biopharmaceutical company’s stock after purchasing an additional 53 shares during the period. Intrust Bank NA’s holdings in Regeneron Pharmaceuticals were worth $1,469,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $31,000. MCF Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $37,000. Finally, Sutton Wealth Advisors Inc. increased its position in Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.0 %

Shares of NASDAQ:REGN traded down $0.30 during mid-day trading on Tuesday, reaching $892.18. 49,701 shares of the stock were exchanged, compared to its average volume of 483,985. The stock’s 50 day simple moving average is $946.89 and its 200-day simple moving average is $894.83. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The company has a market cap of $97.93 billion, a P/E ratio of 25.68, a P/E/G ratio of 2.54 and a beta of 0.11. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $10.96 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on REGN. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Truist Financial reaffirmed a “buy” rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $977.77.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now directly owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Insiders sold a total of 10,195 shares of company stock worth $9,759,898 in the last three months. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.